Abstract Library

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,

#1133 Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location

Introduction: WHO classification of GEP-NET is used to predict prognosis, yet survival within each grade shows wide variation. We hypothesized that primary tumor location may be partially responsible of this variability.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Carmona-Bayonas A

Authors: Carmona-Bayonas A, Jiménez-Fonseca P, Vieitez J, Menendez Prieto M, Soli M,

Keywords: GEP-NET, WHO classification, grade, survival,